Contact
searchSearch
HMP Global

Lymphoma, Leukemia & Myeloma Network

Featured

C. Ola Landgren, MD, PhD
Videos
Updates in Frontline Therapies for Patients With Transplant-Ineligible Multiple Myeloma
03/21/2025
C. Ola Landgren, MD, PhD shares updates on improvements in cancer outcomes, including prolonged survival and tolerability, for patients with newly diagnosed multiple myeloma who are transplant-ineligible.
C. Ola Landgren, MD, PhD shares updates on improvements in cancer outcomes, including prolonged survival and tolerability, for patients with newly diagnosed multiple myeloma who are transplant-ineligible.
C. Ola Landgren, MD, PhD shares...
03/21/2025
Oncology
From Oncology
Michael Green, PhD
Conference Coverage
Potential Impact of Classification of R/R Diffuse Large B-Cell Lymphoma Microenvironment Archetypes on Patient Treatment and Outcomes
03/17/2025
Michael Green, PhD, discusses relapsed/refractory diffuse large B-cell lymphoma microenvironment archetypes and the effect of immunomodulatory and cellular therapies on patient outcomes.
Michael Green, PhD, discusses relapsed/refractory diffuse large B-cell lymphoma microenvironment archetypes and the effect of immunomodulatory and cellular therapies on patient outcomes.
Michael Green, PhD, discusses...
03/17/2025
Oncology
From Oncology
News
Brentuximab Vedotin Plus Lenalidomide and Rituximab Improves Survival For Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
03/17/2025
For patients with relapsed/refractory diffuse large B-cell lymphoma, brentuximab vedotin plus lenalidomide and rituximab was associated with improved survival rates and tolerability, according to results from a phase 3 study.
For patients with relapsed/refractory diffuse large B-cell lymphoma, brentuximab vedotin plus lenalidomide and rituximab was associated with improved survival rates and tolerability, according to results from a phase 3 study.
For patients with...
03/17/2025
Oncology
From Oncology
News
Denileukin Diftitox-CXDL Demonstrates Efficacy for Relapsed/Refractory Cutaneous T-Cell Lymphoma
03/17/2025
A recent phase 3 trial evaluating the use of denileukin diftitox-CXDL for relapsed/refractory cutaneous T-cell lymphoma demonstrated reduced skin tumor burden and promising tolerability.
A recent phase 3 trial evaluating the use of denileukin diftitox-CXDL for relapsed/refractory cutaneous T-cell lymphoma demonstrated reduced skin tumor burden and promising tolerability.
A recent phase 3 trial...
03/17/2025
Oncology
From Oncology
News
Mutation Clearance After Allogeneic Stem Cell Transplantation as Prognostic Indicator for Patients With Myelofibrosis
03/17/2025
For patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation, mutation driver clearance at 30 days was associated with improved cancer outcomes, according to study results.
For patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation, mutation driver clearance at 30 days was associated with improved cancer outcomes, according to study results.
For patients with myelofibrosis...
03/17/2025
Oncology
From Oncology
News
Loncastuximab Tesirine Plus Rituximab Demonstrates Efficacy and Tolerability for Treatment of R/R Follicular Lymphoma
03/07/2025
For patients with relapsed/refractory follicular lymphoma who experience relapse within 24 months after first-line treatment, loncastuximab tesirine plus rituximab shows efficacy and safety, according to a phase 2 trial.
For patients with relapsed/refractory follicular lymphoma who experience relapse within 24 months after first-line treatment, loncastuximab tesirine plus rituximab shows efficacy and safety, according to a phase 2 trial.
For patients with...
03/07/2025
Oncology
From Oncology
Rami Komrokji, MD
Conference Coverage
Risk Stratification and Treatment Strategies for High-Risk Myelodysplastic Syndromes
03/05/2025
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Rami Komrokji, MD discusses the latest updates in risk classification, standard of care, and treatment strategies for myelodysplastic syndromes.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Rami Komrokji, MD discusses the latest updates in risk classification, standard of care, and treatment strategies for myelodysplastic syndromes.
At the 2025 Lymphoma, Leukemia &...
03/05/2025
Oncology
From Oncology
Izidore Lossos, MD
Conference Coverage
Recent Advancements in Treatment of Mantle Cell Lymphoma and Marginal Zone Lymphoma
03/05/2025
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Izidore Lossos, MD shares insights into treatment strategies for patients with mantle cell lymphoma and marginal zone lymphoma.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Izidore Lossos, MD shares insights into treatment strategies for patients with mantle cell lymphoma and marginal zone lymphoma.
At the 2025 Lymphoma, Leukemia &...
03/05/2025
Oncology
From Oncology
Craig Moskowitz, MD
Conference Coverage
Updates in Standard of Care and Disease Management Strategies for Patients With Hodgkin Lymphoma
03/05/2025
Craig Moskowitz, MD discusses updates in the treatment and management of Hodgkin lymphoma for patients in various disease stages at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Craig Moskowitz, MD discusses updates in the treatment and management of Hodgkin lymphoma for patients in various disease stages at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Craig Moskowitz, MD discusses...
03/05/2025
Oncology
From Oncology
News
MRI Radiomics Show Accuracy in Predicting High-Risk Cytogenetic Abnormalities Among Patients With Multiple Myeloma
03/03/2025
High-risk cytogenetic abnormalities, which can be useful to identify for clinical strategy and prognosis evaluation, may be predicted using MRI radiomics among patients with multiple myeloma.
High-risk cytogenetic abnormalities, which can be useful to identify for clinical strategy and prognosis evaluation, may be predicted using MRI radiomics among patients with multiple myeloma.
High-risk cytogenetic...
03/03/2025
Oncology
From Oncology
News
Predictors of Outcomes and Efficacy of Isatuximab, Pomalidomide, and Dexamethasone Therapy for Patients With Daratumumab Refractory MM
03/03/2025
Baseline hemoglobin is a key predictor for cancer outcomes among patients with daratumumab-refractory multiple myeloma treated with isatuximab, pomalidomide, and dexamethasone, according to a real-world investigation.
Baseline hemoglobin is a key predictor for cancer outcomes among patients with daratumumab-refractory multiple myeloma treated with isatuximab, pomalidomide, and dexamethasone, according to a real-world investigation.
Baseline hemoglobin is a key...
03/03/2025
Oncology
From Oncology

Interactive Features

Quiz
Efficacy of Rituximab Maintenance After ASCT Among Patients With Mantle Cell Lymphoma
07/09/2024
True or False: According to a 7.5-year follow-up of the LYMA trial, standard-of-care therapy of rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among...
True or False: According to a 7.5-year follow-up of the LYMA trial, standard-of-care therapy of rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among...
True or False: According to a...
07/09/2024
Lymphoma, Leukemia & Myeloma Network
Quiz
Overall Response Rate of Tafasitamab Plus Lenalidomide for Patients With R/R Diffuse Large B-Cell Lymphoma
06/14/2023
Quiz: According to final results of the phase 2 L-MIND study, what was the overall response rate of tafasitamab plus lenalidomide followed by long-term tafasitamab monotherapy for patients with R/R diffuse large B-cell lymphoma?
Quiz: According to final results of the phase 2 L-MIND study, what was the overall response rate of tafasitamab plus lenalidomide followed by long-term tafasitamab monotherapy for patients with R/R diffuse large B-cell lymphoma?
Quiz: According to final results...
06/14/2023
Oncology
Quiz
Radiomics Features and Prediction of Outcomes for Aggressive B-Cell Lymphoma
06/09/2023
True or False In a study assessing the predictive quality of clinical, molecular genotype, and radiomics features for aggressive B-cell lymphoma, results indicated that radiomics features extracted from baseline 18F-FDG PET/CT scans...
True or False In a study assessing the predictive quality of clinical, molecular genotype, and radiomics features for aggressive B-cell lymphoma, results indicated that radiomics features extracted from baseline 18F-FDG PET/CT scans...
True or False In a study...
06/09/2023
Oncology

Insights

C. Ola Landgren, MD, PhD
Videos
Updates in Frontline Therapies for Patients With Transplant-Ineligible Multiple Myeloma
03/21/2025
C. Ola Landgren, MD, PhD shares updates on improvements in cancer outcomes, including prolonged survival and tolerability, for patients with newly diagnosed multiple myeloma who are transplant-ineligible.
C. Ola Landgren, MD, PhD shares updates on improvements in cancer outcomes, including prolonged survival and tolerability, for patients with newly diagnosed multiple myeloma who are transplant-ineligible.
C. Ola Landgren, MD, PhD shares...
03/21/2025
Oncology
Michael Green, PhD
Conference Coverage
Potential Impact of Classification of R/R Diffuse Large B-Cell Lymphoma Microenvironment Archetypes on Patient Treatment and Outcomes
03/17/2025
Michael Green, PhD, discusses relapsed/refractory diffuse large B-cell lymphoma microenvironment archetypes and the effect of immunomodulatory and cellular therapies on patient outcomes.
Michael Green, PhD, discusses relapsed/refractory diffuse large B-cell lymphoma microenvironment archetypes and the effect of immunomodulatory and cellular therapies on patient outcomes.
Michael Green, PhD, discusses...
03/17/2025
Oncology
Rami Komrokji, MD
Conference Coverage
Risk Stratification and Treatment Strategies for High-Risk Myelodysplastic Syndromes
03/05/2025
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Rami Komrokji, MD discusses the latest updates in risk classification, standard of care, and treatment strategies for myelodysplastic syndromes.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Rami Komrokji, MD discusses the latest updates in risk classification, standard of care, and treatment strategies for myelodysplastic syndromes.
At the 2025 Lymphoma, Leukemia &...
03/05/2025
Oncology
Izidore Lossos, MD
Conference Coverage
Recent Advancements in Treatment of Mantle Cell Lymphoma and Marginal Zone Lymphoma
03/05/2025
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Izidore Lossos, MD shares insights into treatment strategies for patients with mantle cell lymphoma and marginal zone lymphoma.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Izidore Lossos, MD shares insights into treatment strategies for patients with mantle cell lymphoma and marginal zone lymphoma.
At the 2025 Lymphoma, Leukemia &...
03/05/2025
Oncology
Craig Moskowitz, MD
Conference Coverage
Updates in Standard of Care and Disease Management Strategies for Patients With Hodgkin Lymphoma
03/05/2025
Craig Moskowitz, MD discusses updates in the treatment and management of Hodgkin lymphoma for patients in various disease stages at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Craig Moskowitz, MD discusses updates in the treatment and management of Hodgkin lymphoma for patients in various disease stages at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Craig Moskowitz, MD discusses...
03/05/2025
Oncology
Andrew Evens, DO, MBA, MSc
Videos
Therapeutic Breakthroughs and Latest Updates for the Treatment of Follicular Lymphoma
02/28/2025
Andrew Evens, DO, MBA, MSc shared the latest updates and therapeutic advancements for the treatment of follicular lymphoma at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Andrew Evens, DO, MBA, MSc shared the latest updates and therapeutic advancements for the treatment of follicular lymphoma at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Andrew Evens, DO, MBA, MSc...
02/28/2025
Oncology
Joanna Rhodes, MD, MSCE
Videos
Recent Advancements in Frontline Therapy for Patients with R/R Follicular Lymphoma
02/28/2025
Joanna Rhodes, MD, MSCE discusses advances in frontline treatment, including bispecific antibodies and T-cell therapies, for patients with follicular lymphoma at the 20205 Lymphoma, Leukemia & Myeloma Winter Symposium.
Joanna Rhodes, MD, MSCE discusses advances in frontline treatment, including bispecific antibodies and T-cell therapies, for patients with follicular lymphoma at the 20205 Lymphoma, Leukemia & Myeloma Winter Symposium.
Joanna Rhodes, MD, MSCE...
02/28/2025
Oncology
Fadi Haddad, MD
Videos
Latest Strategies for Treating Patients With Chronic Myeloid Leukemia
02/24/2025
Fadi Haddad, MD, shares the most recent updates in the treatment of patients with chronic myeloid leukemia at the 2025 LL&M Winter Symposium in Miami, Florida.
Fadi Haddad, MD, shares the most recent updates in the treatment of patients with chronic myeloid leukemia at the 2025 LL&M Winter Symposium in Miami, Florida.
Fadi Haddad, MD, shares the most...
02/24/2025
Oncology
John Allan, MD
Videos
Novel Targeted Therapies for Patients with Chronic Lymphocytic Leukemia
02/24/2025
John Allan, MD discusses new approaches for chronic lymphocytic leukemia, including CAR T-cell therapies, bispecific antibodies, and BTK degraders, at the 2025 LL&M Winter Symposium.
John Allan, MD discusses new approaches for chronic lymphocytic leukemia, including CAR T-cell therapies, bispecific antibodies, and BTK degraders, at the 2025 LL&M Winter Symposium.
John Allan, MD discusses new...
02/24/2025
Oncology
Victor Jimenez-Zepeda, MD
Videos
Advancements in Treating Patients with Precursor Disorders of Multiple Myeloma
02/24/2025
Victor Jimenez-Zepeda, MD, discusses updates in clinical trials for treatment of smoldering multiple myeloma and monoclonal gammopathy of undetermined significance prior to development of symptomatic multiple myeloma.
Victor Jimenez-Zepeda, MD, discusses updates in clinical trials for treatment of smoldering multiple myeloma and monoclonal gammopathy of undetermined significance prior to development of symptomatic multiple myeloma.
Victor Jimenez-Zepeda, MD,...
02/24/2025
Oncology

Meeting Materials

The Tree That Hides the Forest: An Unfortunate Story of T/NK Lymphoma
Introduction: NK/T lymphoma is a rare type of non-Hodgkin's lymphoma [1,2]. It is a clinical entity that manifests itself essentially by a necrosis that usually starts in the nasal caviti...
11/04/2022
Real-world Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): IONA-MM First Interim Analysis
Introduction:
11/04/2022
Developing an Ontology-Based Platform to Detect Serine Protease Involvement in BALT Lymphoma Patients with COVID-19 & Connect Them to Clinical Trials
Introduction:
11/04/2022

In the News

News
Brentuximab Vedotin Plus Lenalidomide and Rituximab Improves Survival For Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
03/17/2025
For patients with relapsed/refractory diffuse large B-cell lymphoma, brentuximab vedotin plus lenalidomide and rituximab was associated with improved survival rates and tolerability, according to results from a phase 3 study.
For patients with relapsed/refractory diffuse large B-cell lymphoma, brentuximab vedotin plus lenalidomide and rituximab was associated with improved survival rates and tolerability, according to results from a phase 3 study.
For patients with...
03/17/2025
Oncology
News
Denileukin Diftitox-CXDL Demonstrates Efficacy for Relapsed/Refractory Cutaneous T-Cell Lymphoma
03/17/2025
A recent phase 3 trial evaluating the use of denileukin diftitox-CXDL for relapsed/refractory cutaneous T-cell lymphoma demonstrated reduced skin tumor burden and promising tolerability.
A recent phase 3 trial evaluating the use of denileukin diftitox-CXDL for relapsed/refractory cutaneous T-cell lymphoma demonstrated reduced skin tumor burden and promising tolerability.
A recent phase 3 trial...
03/17/2025
Oncology
News
Mutation Clearance After Allogeneic Stem Cell Transplantation as Prognostic Indicator for Patients With Myelofibrosis
03/17/2025
For patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation, mutation driver clearance at 30 days was associated with improved cancer outcomes, according to study results.
For patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation, mutation driver clearance at 30 days was associated with improved cancer outcomes, according to study results.
For patients with myelofibrosis...
03/17/2025
Oncology
News
Loncastuximab Tesirine Plus Rituximab Demonstrates Efficacy and Tolerability for Treatment of R/R Follicular Lymphoma
03/07/2025
For patients with relapsed/refractory follicular lymphoma who experience relapse within 24 months after first-line treatment, loncastuximab tesirine plus rituximab shows efficacy and safety, according to a phase 2 trial.
For patients with relapsed/refractory follicular lymphoma who experience relapse within 24 months after first-line treatment, loncastuximab tesirine plus rituximab shows efficacy and safety, according to a phase 2 trial.
For patients with...
03/07/2025
Oncology
News
MRI Radiomics Show Accuracy in Predicting High-Risk Cytogenetic Abnormalities Among Patients With Multiple Myeloma
03/03/2025
High-risk cytogenetic abnormalities, which can be useful to identify for clinical strategy and prognosis evaluation, may be predicted using MRI radiomics among patients with multiple myeloma.
High-risk cytogenetic abnormalities, which can be useful to identify for clinical strategy and prognosis evaluation, may be predicted using MRI radiomics among patients with multiple myeloma.
High-risk cytogenetic...
03/03/2025
Oncology
News
Predictors of Outcomes and Efficacy of Isatuximab, Pomalidomide, and Dexamethasone Therapy for Patients With Daratumumab Refractory MM
03/03/2025
Baseline hemoglobin is a key predictor for cancer outcomes among patients with daratumumab-refractory multiple myeloma treated with isatuximab, pomalidomide, and dexamethasone, according to a real-world investigation.
Baseline hemoglobin is a key predictor for cancer outcomes among patients with daratumumab-refractory multiple myeloma treated with isatuximab, pomalidomide, and dexamethasone, according to a real-world investigation.
Baseline hemoglobin is a key...
03/03/2025
Oncology
News
Second High-Dose Therapy and Autologous Stem Cell Transplant Demonstrates Efficacy and Tolerability for Patients With MM in First Relapse
03/03/2025
For patients who previously received high dose therapy/autologous stem cell transplantation (HDT/ASCT) for multiple myeloma, second consolidation HDT/ASCT may improve cancer outcomes, according to a retrospective study.
For patients who previously received high dose therapy/autologous stem cell transplantation (HDT/ASCT) for multiple myeloma, second consolidation HDT/ASCT may improve cancer outcomes, according to a retrospective study.
For patients who previously...
03/03/2025
Oncology
News
Venetoclax and Hypomethylating Agent Treatment Shows Efficacy for R/R Acute Myeloid Leukemia, With Genetic Predictors of Response Identified
02/28/2025
Venetoclax plus hypomethylating agents demonstrated efficacy for treating R/R AML, with genetic features, including distinct mutations, predicting response to treatment, according to a retrospective study.
Venetoclax plus hypomethylating agents demonstrated efficacy for treating R/R AML, with genetic features, including distinct mutations, predicting response to treatment, according to a retrospective study.
Venetoclax plus hypomethylating...
02/28/2025
Oncology
News
Autologous Hematopoietic Stem Cell Transplantation as Additional Treatment Option for Secondary Acute Myeloid Leukemia
02/28/2025
While allogeneic hematopoietic stem cell transplantation is the standard treatment for secondary AML, autologous hematopoietic stem cell transplantation shows promising outcomes as an additional treatment option, according to a retrospective...
While allogeneic hematopoietic stem cell transplantation is the standard treatment for secondary AML, autologous hematopoietic stem cell transplantation shows promising outcomes as an additional treatment option, according to a retrospective...
While allogeneic hematopoietic...
02/28/2025
Oncology
News
GPRC5D-Targeted CAR T-Cell Therapy Demonstrates Efficacy and Safety for Patients With R/R MM
02/24/2025
CAR T-Cell therapy targeting GPRC5D was found to be safe and effective for the treatment of relapsed/refractory multiple myeloma, according to a recent systematic meta-analysis.
CAR T-Cell therapy targeting GPRC5D was found to be safe and effective for the treatment of relapsed/refractory multiple myeloma, according to a recent systematic meta-analysis.
CAR T-Cell therapy targeting...
02/24/2025
Oncology

Latest Podcasts

Podcasts
Dr Leonard Shares Highlights to Expect at the 2020 Lymphoma, Leukemia & Myeloma Congress
10/19/2020
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what...
10/19/2020
Oncology
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
Podcasts
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
08/24/2020
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an...
08/24/2020
Oncology
Podcasts
Seattle Children's Hospital Leukemia Program Offers Multidisciplinary Care to Underserved Population
06/19/2018
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new...
06/19/2018
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use